Automating breast cancer detection with deep learning
blog.insightdatascience.com
blog.insightdatascience.com
I've worked in labs that do this exact same thing. It's cool that they're putting this in a consumer-facing format but the technology (re: accuracy in ML models) still isn't there yet, and there are a lot more performant and sophisticated models than the relatively simple network architectures the authors describe. At risk of being overly critical of the author, to me this just seems like a first, rather naive implementation of ML to be shown as a proof of being able to do ML related things, with the actual performance or usefulness of the model being secondary to that.
In short, putting this into practice at a consumer level: good. Actual modelling: maybe not so good.
> I've worked in labs that do this exact same thing. It's cool that they're putting this in a consumer-facing format but the technology (re: accuracy in ML models) still isn't there yet
Don't these observations explain each other? The whole point of have a consumer product is to reduce office visits and/or increase the monitoring frequency. So reduced accuracy is acceptable since any positive results would be followed up by the standard, more sophisticated tests.
They aren't trying to mimic the state of the art in a phone.
False negative (24%) means you are not getting the treatment you need as soon as you could. Imagine people delaying a real mammogram for a few years because they have an app that says "all good!".
False positive (35%) means unneeded tests and doctors visits. This is less concerning as a bad outcome, but it does mean more stress , more expense and longer wait times to schedule a doctor visit.
This is an interesting exercise in ML, but there is little chance this app would get approval as a diagnostic tool.
Also, FTA:
> The code will be the deliverable to iSono Health as a baseline model for further algorithm development.
A game-changer in cancer treatment would be "early detection". Once it gets to be inexpensive to analyze images, then we can have vastly earlier cancer detection...you could work into a scanning machine in a local pharmacy, get scanned & get the analysis right there...you could go in for monthly scans. Theranos had something of that vision with a drop of blood in pharmacies which could also provide very early detection of cancer...but they didn't execute technically among other issues.
Because the data augmentation is performed prior to the random train/val/test split, nearly identical instances may be found in each set. In other words, a 1 degree rotation of training image X may be found in the validation or test set which would artificially inflate performance.
I note they didn't give a ROC curve or d'.
Honestly the more interesting case is probably this + mammo, as there is research suggesting sensitivity increases with US + mammo, over mammo alone.
So it's worth looking at.
What they have now is worse than useless, though.
https://www.google.co.nz/amp/s/www.washingtonpost.com/amphtm...